• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Quest PharmaTech receives $8 million investment for oregovomab trials

Quest PharmaTech receives $8 million investment for oregovomab trials

June 6, 2012
CenterWatch Staff

Quest PharmaTech, an Alberta-based biotech developing and commercializing products for the treatment of cancer, has received an $8 million investment from parties of South Korea to support its clinical trial programs.

The investment agreement, which ensures funding for the next 12 months, will be used to accelerate the Quest’s ongoing Italian and pending U.S. oregovomab clinical trial, and to re-initiate the anti-MUC1 clinical trial program. Oregovomab is a high affinity monoclonal antibody for the treatment of advanced ovarian cancer that targets the circulating tumor associated antigen CA125.

The agreement also issues up to 15,000,000 common shares to the South Korean parties and undisclosed terms associated with successful commercialization. As the shares to be issued may create a “control person” (an investor holding greater than 20% of Quest's shares), shareholder approval will be sought for the investment arrangement at Quest's upcoming AGM to be held on July 26, 2012.

In the meantime, Quest has received a $500,000 interest free loan from Gi Ho Park, an insider of Quest. As funding under the $8 million investment arrangement is received, Quest will repay the $500,000 bridge loan, or the amount could be converted into Quest's common shares at the higher of $0.40 per share or the market price of Quest's common shares at the time of conversion, less than a 10% discount.

The issuance of Quest common shares will be subject to TSX Venture Exchange approval.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing